<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281671</url>
  </required_header>
  <id_info>
    <org_study_id>05-12-160</org_study_id>
    <nct_id>NCT00281671</nct_id>
  </id_info>
  <brief_title>Nesiritide Use Following Cardiac Surgery in Infants</brief_title>
  <official_title>Pilot Study of the Effects of Nesiritide on Hemodynamics and Urine Output Following Cardiopulmonary Bypass in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of nesiritide on urine output and&#xD;
      hemodynamics following cardiopulmonary bypass in infants. Safety and pharmacokinetic data&#xD;
      will also be obtained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nesiritide, a recombinant human B-type natriuretic peptide, has vasodilatory, lusitropic and&#xD;
      diuretic properties in healthy humans, and improves hemodynamics and symptoms in adults with&#xD;
      decompensated congestive heart failure. Several retrospective case series suggest that&#xD;
      nesiritide has beneficial effects on hemodynamics and urine output in adults and children&#xD;
      following cardiac surgery.&#xD;
&#xD;
      The purpose of this prospective, randomized, double-blind, crossover study is to evaluate the&#xD;
      effects of a continuous infusion of nesiritide on postoperative hemodynamics and urine output&#xD;
      in infants with congenital heart disease who undergo cardiac surgery requiring&#xD;
      cardiopulmonary bypass (CPB). Patients less than 1 year of age following cardiac surgery will&#xD;
      be eligible for the study if they have received two conventional diuretics (furosemide and&#xD;
      chlorothiazide) for at least 12 hours, yet are not effectively achieving a negative fluid&#xD;
      balance, thus prohibiting sternal closure or tracheal extubation. Patients will be randomized&#xD;
      to receive either a 10-hour infusion of nesiritide, a two hour washout period, followed by a&#xD;
      10-hour infusion of placebo, or this study drug sequence in reverse order. During the 24-hour&#xD;
      study period, serial cardiac output measurements and BNP levels will be obtained, vital signs&#xD;
      and intracardiac filling pressures will be recorded, and urine output will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow patient enrollment.&#xD;
  </why_stopped>
  <start_date>April 8, 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Output</measure>
    <time_frame>5 hours</time_frame>
    <description>Urine output measured in cc/kg/hour during the last 5 hours of the study drug infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypotension and Bradycardia</measure>
    <time_frame>48 hours</time_frame>
    <description>Hypotension (mean arterial blood pressure &lt; 40 mmHg for &gt; 30 minutes) that is refractory to volume administration, increased inotropic/vasopressor support, and weaning of other vasodilators (e.g., milrinone) or sedatives&#xD;
Bradycardia, defined as 1) a decrease in heart rate of more than 30 beats/minute from baseline following the initiation of study drug infusion that 2) results in new requirement for temporary atrial pacing or other treatment specifically to increase heart rate and 3) is not readily explainable by other conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Output</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>Baseline (hour 0) and 6 hours after onset of study drug infusion</time_frame>
    <description>Cardiac index is based on the cardiac output, which is the amount of blood the left ventricle ejects into the systemic circulation in one minute, measured in liters per minute (l/min). Cardiac output is indexed to a patient's body size by dividing by the body surface area (m^2) to yield the cardiac index. Cardiac index was calculated in patients with an SVC catheter (previously placed for clinical indications) using the Fick principle using measured oxygen consumption (VO2), hemoglobin levels, and the difference between arterial and superior vena cava oxygen saturation. Oxygen consumption was measured using a real-time gas exchange technique with the Deltatrack II gas sensor.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nesiritide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nesiritide</intervention_name>
    <description>nesiritide 0.015 mcg/kg/hour x 10 hours</description>
    <arm_group_label>Nesiritide</arm_group_label>
    <other_name>Natrecor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 48 hours after cardiac surgery requiring cardiopulmonary bypass&#xD;
&#xD;
          -  &lt; 1 year of age&#xD;
&#xD;
          -  Receiving chlorothiazide and furosemide for &gt; 12 hours&#xD;
&#xD;
          -  Urine output &lt; 4 cc/kg/hour, or fluid intake &gt; output for 2 consecutive days&#xD;
&#xD;
          -  Receiving mechanical ventilation&#xD;
&#xD;
          -  Presence of body wall edema on CXR, defined as a radiologic index of &gt; 2&#xD;
&#xD;
          -  Plan for &gt; 24 hrs further diuresis before chest closure or extubation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 365 days at the time of enrollment&#xD;
&#xD;
          -  Corrected estimated gestational age &lt; 35 weeks at the time of enrollment&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL at the time of enrollment&#xD;
&#xD;
          -  Significant hemodynamic instability at the time of enrollment&#xD;
&#xD;
          -  Lack of dedicated intravenous access for nesiritide infusion&#xD;
&#xD;
          -  Lack of arterial line for continuous blood pressure monitoring&#xD;
&#xD;
          -  Lack of a Foley catheter for continuous urine collection&#xD;
&#xD;
          -  Enrollment in another research study such that the outcomes of either study may be&#xD;
             confounded by participation in this study, or such that the amount of blood drawn for&#xD;
             research purposes becomes excessive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Costello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Children's Hospital Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Costello JM, Backer CL, Checchia PA, Mavroudis C, Seipelt RG, Goodman DM. Effect of cardiopulmonary bypass and surgical intervention on the natriuretic hormone system in children. J Thorac Cardiovasc Surg. 2005 Sep;130(3):822-9.</citation>
    <PMID>16153935</PMID>
  </reference>
  <reference>
    <citation>Costello JM, Backer CL, Checchia PA, Mavroudis C, Seipelt RG, Goodman DM. Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure. Pediatr Cardiol. 2004 Jul-Aug;25(4):347-53.</citation>
    <PMID>14735254</PMID>
  </reference>
  <reference>
    <citation>Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med. 2005 Sep;6(5):543-6.</citation>
    <PMID>16148814</PMID>
  </reference>
  <reference>
    <citation>Simsic JM, Reddy VS, Kanter KR, Kirshbom PM, Forbess JM. Use of nesiritide (human B-type natriuretic peptide) in infants following cardiac surgery. Pediatr Cardiol. 2004 Nov-Dec;25(6):668-70.</citation>
    <PMID>14994182</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <results_first_submitted>February 26, 2018</results_first_submitted>
  <results_first_submitted_qc>August 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2020</results_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>John M Costello</investigator_full_name>
    <investigator_title>Attending Physician, Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Nesiritide</keyword>
  <keyword>Natriuretic Peptide, Brain</keyword>
  <keyword>Heart Defects, Congenital</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Diuretics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Email PI for data requests.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment: April 2006- June 2007.&#xD;
Location: Cardiac ICU in a large children's hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nesiritide First, Then Placebo</title>
          <description>Patients assigned to this arm received nesiritide 0.015 mcg/kg/hour for 10 hours, followed by a two hour washout period, and then a placebo infusion (0.9 normal saline) for 10 hours</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Nesiritide</title>
          <description>Patients assigned to this arm received a placebo infusion (0.9 normal saline) for 10 hours, followed by a two hour washout period, and then nesiritide 0.015 mcg/kg/hour for 10 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Because all participants were randomized to receive all interventions, baseline measurements are combined rather that reported by Arm/Group.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="4" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Northeast United States</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="2.5" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prematurity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urine Output</title>
        <description>Urine output measured in cc/kg/hour during the last 5 hours of the study drug infusion</description>
        <time_frame>5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In this crossover pilot study, patients were randomly assigned to receive either nesiritide 0.015 mcg/kg/min or placebo IV infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
For this arm, the data reflect the urine output during the last 5 hours of the 0.9 normal saline placebo infusion for all 9 patients.</description>
          </group>
          <group group_id="O2">
            <title>Nesiritide</title>
            <description>In this crossover pilot study, patients are randomly assigned to receive either nesiritide 0.015 mcg/kg/min or placebo IV infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
For this arm, the data reflect the urine output during the last 5 hours of the nesiritide 0.015 mcg/kg/hour infusion for all 9 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Output</title>
          <description>Urine output measured in cc/kg/hour during the last 5 hours of the study drug infusion</description>
          <units>cc/kg/hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.1" upper_limit="7.1"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.6" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypotension and Bradycardia</title>
        <description>Hypotension (mean arterial blood pressure &lt; 40 mmHg for &gt; 30 minutes) that is refractory to volume administration, increased inotropic/vasopressor support, and weaning of other vasodilators (e.g., milrinone) or sedatives&#xD;
Bradycardia, defined as 1) a decrease in heart rate of more than 30 beats/minute from baseline following the initiation of study drug infusion that 2) results in new requirement for temporary atrial pacing or other treatment specifically to increase heart rate and 3) is not readily explainable by other conditions.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In this crossover pilot study, patients were randomly assigned to receive either nesiritide 0.015 mcg/kg/min or placebo IV infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
For this arm, the data reflect the urine output during the last 5 hours of the 0.9 normal saline placebo infusion for all 9 patients.</description>
          </group>
          <group group_id="O2">
            <title>Nesiritide</title>
            <description>In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
For this arm, the data reflect the urine output during the last 5 hours of the nesiritide 0.015 mcg/kg/hour infusion for all 9 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypotension and Bradycardia</title>
          <description>Hypotension (mean arterial blood pressure &lt; 40 mmHg for &gt; 30 minutes) that is refractory to volume administration, increased inotropic/vasopressor support, and weaning of other vasodilators (e.g., milrinone) or sedatives&#xD;
Bradycardia, defined as 1) a decrease in heart rate of more than 30 beats/minute from baseline following the initiation of study drug infusion that 2) results in new requirement for temporary atrial pacing or other treatment specifically to increase heart rate and 3) is not readily explainable by other conditions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Output</title>
        <time_frame>10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In this crossover pilot study, patients are randomly assigned to receive either nesiritide 0.015 mcg/kg/min or placebo IV infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
nesiritide: nesiritide 0.015 mcg/kg/hour x 10 hours</description>
          </group>
          <group group_id="O2">
            <title>Nesiritide</title>
            <description>In this crossover pilot study, patients are randomly assigned to receive either nesiritide 0.015 mcg/kg/min or placebo IV infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
nesiritide: nesiritide 0.015 mcg/kg/hour x 10 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Output</title>
          <units>cc/kg/hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.1" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.3" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Index</title>
        <description>Cardiac index is based on the cardiac output, which is the amount of blood the left ventricle ejects into the systemic circulation in one minute, measured in liters per minute (l/min). Cardiac output is indexed to a patient's body size by dividing by the body surface area (m^2) to yield the cardiac index. Cardiac index was calculated in patients with an SVC catheter (previously placed for clinical indications) using the Fick principle using measured oxygen consumption (VO2), hemoglobin levels, and the difference between arterial and superior vena cava oxygen saturation. Oxygen consumption was measured using a real-time gas exchange technique with the Deltatrack II gas sensor.</description>
        <time_frame>Baseline (hour 0) and 6 hours after onset of study drug infusion</time_frame>
        <population>Cardiac index was only able to be measured for 4 of the 9 subjects enrolled in the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In this crossover pilot study, patients were randomly assigned to receive either nesiritide 0.015 mcg/kg/min or placebo IV infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
For this arm, the data reflect the urine output during the last 5 hours of the 0.9 normal saline placebo infusion for all 9 patients.</description>
          </group>
          <group group_id="O2">
            <title>Nesiritide</title>
            <description>In this crossover pilot study, patients are randomly assigned to receive either nesiritide 0.015 mcg/kg/min or placebo IV infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.&#xD;
For this arm, the data reflect the urine output during the last 5 hours of the nesiritide 0.015 mcg/kg/hour infusion for all 9 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Index</title>
          <description>Cardiac index is based on the cardiac output, which is the amount of blood the left ventricle ejects into the systemic circulation in one minute, measured in liters per minute (l/min). Cardiac output is indexed to a patient's body size by dividing by the body surface area (m^2) to yield the cardiac index. Cardiac index was calculated in patients with an SVC catheter (previously placed for clinical indications) using the Fick principle using measured oxygen consumption (VO2), hemoglobin levels, and the difference between arterial and superior vena cava oxygen saturation. Oxygen consumption was measured using a real-time gas exchange technique with the Deltatrack II gas sensor.</description>
          <population>Cardiac index was only able to be measured for 4 of the 9 subjects enrolled in the trial.</population>
          <units>L/min/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="0.95" upper_limit="3.61"/>
                    <measurement group_id="O2" value="1.90" lower_limit="1.50" upper_limit="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after onset of drug infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" lower_limit="1.40" upper_limit="5.80"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.42" upper_limit="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Initiation of study interventions until 48 hours after the study drug infusions ended.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nesiritide</title>
          <description>Patients received nesiritide 0.015 mcg/kg/hour for 10 hours</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients assigned to this arm received a placebo infusion (0.9 normal saline) for 10 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John M. Costello, MD MPH</name_or_title>
      <organization>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</organization>
      <phone>312 227 1551</phone>
      <email>jmcostello@luriechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

